Echocardiography Imaging Can Identify COVID-19 Patients Predisposed to Heart Failure Who Face Higher Mortality Risk

First-phase ejection fraction, a possible indicator of heart failure, when measured with conventional echocardiography imaging can be a strong predictor of survival in hospitalized COVID-19 patients, according to a new study.

First-phase ejection fraction could be a new way to identify patients at elevated risk of dying from COVID-19 and possibly other types of pneumonia, according to researchers at St. Thomas' Hospital (London, UK) who conducted the study. The researchers found that hospitalized patients who had impaired first-phase ejection fraction were nearly five times more likely to die from COVID-19 compared to patients with normal first-phase ejection fraction. First-phase ejection fraction is a measure of the left ventricular ejection fraction until the time of maximal ventricular contraction.


Cardiovascular risk factors and/or disease have been recognized as COVID-19 risk factors that have a high negative impact on patient outcomes, since early in the SARS-CoV-2 pandemic. Researchers hypothesized that predisposition to heart failure would be associated with more severe cases of COVID-19 in hospitalized patients. To determine if first-phase ejection fraction predicted adverse patient outcomes, researchers analyzed mortality rates for 129 hospitalized COVID-19 patients in Wuhan, China, and 251 hospitalized COVID-19 patients in South London, treated between February and May 2020, were analyzed. All patients had echocardiography upon hospital admission, and the average patient age was 58 years. Researchers compared echocardiography results of COVID-19 patients to adult patients with otherwise similar health profiles who had an echocardiography test before the pandemic.

First-phase ejection fraction was measured with conventional echocardiography imaging conducted at hospitalized patients' bedsides. Researchers note that there is not a universally established 'normal' value for first-phase ejection fraction. Based on previous research, they estimated that the normal first-phase ejection fraction value should be above 25%. When first-phase ejection fraction was less than 25%, researchers referred to it as 'impaired,' suggesting relatively subtle signs of heart damage. The researchers found that COVID-19 patients with a first-phase ejection fraction of less than 25% had a nearly five-fold higher risk of death than those with an ejection fraction of 25% or higher. They also found that a similar proportion of people with similar risk factors who did not have COVID-19 had low values of first-phase ejection fraction. This suggests that the damage to the heart may be due to chronic pre-existing conditions and was not the result of COVID-19 infection.

"Patients with impaired first-phase ejection fraction could be prioritized for vaccines and, if they get COVID-19, monitored closely at the early stages of their illness to prevent deterioration," said study author Phil Chowienczyk, M.B.B.S., B.Sc., professor of cardiovascular clinical pharmacology at St. Thomas' Hospital. "The findings suggest that if we can prevent the very early chronic damage to the heart detected using first-phase ejection fraction imaging, then people will be much more likely to survive respiratory infections like COVID-19. Healthy lifestyle choices, better treatments and adherence to treatments for high blood pressure and high cholesterol are also important."


Related Links:
St. Thomas' Hospital